Given the association of ADAb positivity with reduced therapeutic response, it is not surprising that a higher proportion of our RA patients with anti-TROVE2 (anti-Ro60/SSA) antibody had poor EULAR response compared to those without this antibody. This evidence concerns the gene TRIM21 and rheumatoid arthritis.